GW&K Investment Management LLC Lowers Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

GW&K Investment Management LLC cut its stake in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 7.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 817,071 shares of the company's stock after selling 69,863 shares during the quarter. GW&K Investment Management LLC owned 1.67% of Cryoport worth $12,657,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of CYRX. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Cryoport by 13.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company's stock worth $157,000 after acquiring an additional 1,395 shares during the period. WINTON GROUP Ltd bought a new stake in shares of Cryoport during the 3rd quarter valued at about $163,000. Pathstone Family Office LLC bought a new stake in shares of Cryoport during the 3rd quarter valued at about $165,000. Quantbot Technologies LP boosted its stake in shares of Cryoport by 109.0% during the 3rd quarter. Quantbot Technologies LP now owns 12,838 shares of the company's stock valued at $176,000 after purchasing an additional 6,694 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Cryoport during the 4th quarter valued at about $202,000. 92.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Edward J. Zecchini sold 3,443 shares of the firm's stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $13.37, for a total value of $46,032.91. Following the sale, the insider now owns 60,051 shares in the company, valued at $802,881.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Jerrell Shelton sold 3,723 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $16.35, for a total value of $60,871.05. Following the transaction, the chief executive officer now owns 636,951 shares in the company, valued at approximately $10,414,148.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Edward J. Zecchini sold 3,443 shares of the business's stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $13.37, for a total transaction of $46,032.91. Following the sale, the insider now owns 60,051 shares of the company's stock, valued at $802,881.87. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,488 shares of company stock valued at $1,302,259. Insiders own 10.10% of the company's stock.

Cryoport Stock Down 3.1 %

Cryoport stock traded down $0.37 during trading hours on Wednesday, hitting $11.52. The stock had a trading volume of 261,313 shares, compared to its average volume of 454,953. The company has a quick ratio of 10.22, a current ratio of 10.73 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $567.48 million, a P/E ratio of -4.66 and a beta of 1.60. Cryoport, Inc. has a 12-month low of $9.00 and a 12-month high of $23.50. The stock's 50-day moving average price is $16.08 and its 200-day moving average price is $15.42.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Tuesday, May 7th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The firm had revenue of $54.59 million during the quarter, compared to analysts' expectations of $58.78 million. Cryoport had a negative return on equity of 15.19% and a negative net margin of 50.17%. The firm's quarterly revenue was down 13.1% on a year-over-year basis. During the same period last year, the firm posted ($0.16) earnings per share. Equities research analysts anticipate that Cryoport, Inc. will post -1.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CYRX has been the topic of a number of research reports. B. Riley lowered shares of Cryoport from a "buy" rating to a "neutral" rating and cut their target price for the company from $22.00 to $19.00 in a research note on Friday, May 3rd. Stephens reaffirmed an "equal weight" rating and set a $17.00 target price on shares of Cryoport in a research note on Wednesday, March 13th. Jefferies Financial Group initiated coverage on shares of Cryoport in a research note on Thursday, April 4th. They set a "buy" rating and a $21.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $18.00 price target on shares of Cryoport in a research report on Wednesday, May 8th. Finally, UBS Group lifted their price target on shares of Cryoport from $14.50 to $17.00 and gave the company a "neutral" rating in a research report on Friday, March 15th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $18.25.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.